CDH2 and meningioma: By integrating our bioinformatic, histopathologic and radiologic findings with our human cerebral organoid model of meningioma, we identify CDH2 and PTPRZ1 as genes that are enriched in high ADC regions that drive meningioma tumorigenesis and represent novel targets for molecular therapy to treat meningioma patients.